Providing answers for cancer patients

curasight

Curasight A/S
Interim report Q1 2024

In this document, the following definitions shall apply unless otherwise specified: “the Company” or “Curasight” refers to Curasight A/S, CVR no. 35249389.

The Company
CURASIGHT A/S
Ole Maaløes Vej 3
2200 København N
Tel.: 22 83 01 60
Registered office: København N
CVR no.: 35 24 93 89
Financial year: 01.01 - 31.12

Key figures and selected posts

Q1 (2024-01-01 – 2024-03-31)

- Gross loss amounted to kDKK -7,385 (kDKK -4,656)
- Operating loss amounted to kDKK -9,376 (kDKK -6,184)
- Loss before tax amounted to kDKK -9,367 (kDKK -6,186)
- Loss for the period amounted to kDKK -7,992 (kDKK -4,826)
- Total assets amounted to kDKK 27,574 (kDKK 54,745)
- Equity ratio amounted to 84,8% (96,3%)
- Earnings per share amounted to DKK -0,40 (DKK -0,24)

Numbers in parenthesis are the numbers from the same period in 2023.

Definitions
Equity ratio: Shareholders equity as a proportion of total assets.
Earnings per share: Profit/Loss for the period divided by average number of shares.

Strong momentum in our partnership with Curium and continued focus on securing funding for our development plans

During the first quarter of 2024, we have continued to build on our successes from the past year. We were particularly pleased to receive the first milestone payment from Curium under our agreement for uTRACE®, an important step achieved in less than a year since signing the collaboration. We also updated our clinical strategy to accelerate development of our therapeutic platform uTREAT® and ensure parallel development with our uTRACE® diagnosis platform.

This refined development strategy is in line with our theranostic platform approach to use radiopharmaceutical solutions for both improved diagnosis and treatment of certain cancers.

Navigating financial and strategic horizons

The current climate in the biotech capital market is still challenging, as reflected in our decision to withdraw the planned rights issue back in March of Q1. We are committed to securing funding for the company in a way that is most beneficial for shareholders and we look forward to being able to announce progress in the area of alternative funding options soon. We are also working hard on progressing our newly updated clinical strategy to accelerate development of uTREAT®.

The sharpened focus on our therapeutic platform reflects current thinking in both the scientific community and the pharmaceutical industry to provide a combined approach for both diagnosis and treatment. During Q1 we announced our aim to investigate clinically uTREAT® across five different cancer types to achieve clinical proof of concept for our therapy option.

On the diagnostic side of our theranostics solution, since signing the partnership with Curium last year for the development of uTRACE® in prostate cancer, we have moved rapidly. We were therefore delighted to be able to show this progress with the announcement of the first milestone related to validation of GMP manufacturing of the finished product.

Anticipating progress in 2024

Looking ahead to the rest of 2024, we anticipate further progress in our pipeline as well as more intense discussions with different potential partners in the industry as Radionuclide Ligand Therapy (RLT) continues to be in focus as an important option within radiotherapy in cancer.

As mentioned, we expect to be able to announce additional funding to the market soon with the effort to accelerate our clinical pipeline, and continue to ensure value creation for our shareholders and at the same time contribute meaningfully to cancer treatment for patients in need.

In conclusion, I extend my gratitude for your continued trust in Curasight.

Best Regards,
Ulrich Krasilnikoff
CEO, Curasight A/S

Highlights Q1 and after

On January 22, Curasight announced the achievement of the first milestone under the agreement with Curium inc., to develop Curasight's uTRACE® PET imaging technology for the improved diagnosis of prostate cancer. The milestone relates to the validation of GMP manufacturing of the finished product.

On February 13, Curasight announced that the Company is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design. The trial will investigate Curasight's theranostic (therapeutics/diagnostics) approach by testing the diagnostic platform uTRACE® and the treatment platform uTREAT® in brain cancer (Glioblastoma), neuroendocrine tumors (NET), head-and-neck cancer (HNSCC), non-small cell lung cancer (NSCLC), and pancreatic cancer. To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.

On February 13, Curasight resolved on a new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs. The proceeds are intended to be used to strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, including the preparation, planning and enrolment of the first patients in a therapy phase I/IIa basket trial in various cancer types, as well as to strengthen Curasight's pipeline through preclinical development of new peptide-based radioligands.

On March, 11, Curasight announced that it will not proceed with the Rights Issue announced on February 13th 2024. The Company remains committed to accelerating its therapeutic strategy and is currently evaluating alternative financing options.

On April 12, Curasight announced that the Chair of the Board of Directors, Per Falholt, has announced that he wishes to step down from the Board of Directors with immediate effect. Kirsten Drejer has been elected as the new Chair of the Board of Directors.

On April 16, Curasight announced the approval of a clinical trial application (CTA) from the European Medicines Agency (EMA) for the investigation of uTRACE® in a phase 2 trial as a non-invasive alternative or supplement to traditional biopsies in prostate cancer patients in active surveillance.



By combining diagnostics with therapy – Curasight is on a mission to improve the lives of millions of people with cancer

Curasight A/S in short

Curasight is a clinical phase II company based in Copenhagen, Denmark. Curasight is the pioneer behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy with the precise uTRACE® diagnostics. Several investigator-initiated phase II clinical trials have been completed or are currently undertaken.

PET-imaging, usually combined with CT as PET/CT is used to create images in which the biology of the disease can be studied. The principle is that a radiolabelled tracer is injected and bound to the tumor targets in the tissues, e.g. uPAR, after which the radioactivity can be located with the help of a PET-scanner. Together with his team, Professor Andreas Kjaer, developed a platform based on the radiolabelled PET-tracer uTRACE®, Curasight's novel product that highlights the cancer biomarker uPAR. By injecting the patient with uTRACE®, one can both image where the cancer is located and determine its level of aggressiveness.

uTRACE images cancer aggressiveness and invasive potential. By imaging this, Curasight's technology can diagnose and determine which therapeutic strategy should be pursued, e.g. if the patient needs treatment (e.g. surgery such as prostatectomy and/or radiotherapy) or not. In addition, uTRACE® will be used for theranostics (principle of combined therapy and diagnostics) and precision medicine, selecting the right therapy to the right person at the right time, creating substantial benefits for both patients and the healthcare system.

uTRACE solution is expected to have major advantages in the future evaluation of prostate cancer because it is expected to help determine what type of treatment – and in particular if surgery – is necessary. Today most prostate cancer patients having prostatectomies performed are operated unnecessarily and most of these patients (up to 70 percent) experience some degree of side effects, such as impotence. The company believes that using Curasight's product and diagnosis could improve patient management. uTRACE® is designed to provide a more accurate categorisation of a patient's tumor, supporting more tailored treatment plans allowing which can identify the necessary treatment at the right time.

Curasight's technology has been tested phase II academic clinical trials. According to the board's assessments, there is currently no other early-stage biotech company in the field of PET tracer development that has their technology tested in a broader portfolio of ongoing and planned clinical trials in humans (whether investigator-initiated and academically sponsored or industry-sponsored trials), in many different cancer indications. In 2017 a phase I/IIa first-in-human academic clinical trial with uTRACE® was completed. In 2018 a phase IIb academic clinical trial with uTRACE® in breast cancer; in 2020 a phase II academic study in prostate cancer in 2021/2022 two academic studies in head-and-neck cancer and neuroendocrine tumors, respectively, were completed, and in 2023 the study in brain cancer was completed. A study in lung cancer is ongoing.



Targeted radionuclide therapy (theranostics) is expected to be the radiation therapy of the future. With the promising results obtained within diagnostics, Curasight now also pursues uPAR targeted radionuclide therapy using the uTRACE® ligand but "armed" with short-range (1 mm) radiation therapy. In brief, the therapeutic ligand will be injected into a vein after which it will circulate and bind to all cancer cells in the body expressing uPAR and locally irradiate cancer with limited irradiation of healthy tissue. This concept represents a gentler form of radiotherapy compared to traditional external radiation therapy and is therefore by many considered the "radiation therapy of tomorrow". As PET imaging and radionuclide therapy are based on the same uPAR binding peptide, a uTRACE®-scan can precisely predict where subsequent targeted radiation therapy will be delivered (theranostic principle).

Business model and critical path to regulatory approval

Curasight aims to etablish its theranostic approach using imaging targeting the uPAR protein to improve the diagnosis and treatment of selective cancers. The company's uTRACE® platform can be used as an alternative to biopsies to discover and characterise tumors and the uTREAT® platform can then be used for more targeted treatment of the tumor.

Currently Curasight is focused on generating data with both uTRACE® and uTREAT® in cancers including prostate cancer, glioblastoma (brain cancer), neuroendocrine tumors (NET), head and neck cancer, non small cell lung cancer (NSCLC), and pancreatic cancer. Each of these cancers offer different development opportunities and it is Curasight's aim, based on clinical data, to find experienced partners who can collaborate on the later stages of development of uTRACE® and uTREAT®. Currently Curasight has a partnership for uTRACE® in prostate cancer with Curium, a leader in the field of radionuclide medicine.

Additionally, as a small and nimble company, Curasight seeks out highly specialised partners to support its operational drug development, for example with research and clinical contract organisations who are highly competent in the field of both diagnostic and therapeutic radiopharmaceuticals. By forming partnerships with Contract Development Manufacturing Organisations (CDMOs), and Clinical Research Organisations (CROs) we ensure access to top development manufacturing expertise and capacity and skills in conducting manufacturing of investigational medicine and clinical trials in accordance with good manufacturing (GMP) and clinical practice (GCP). We have now signed an agreement with Minerva Imaging ApS considered to be the optimal CDMO for the manufacture of the Investigational Medicinal Product for our coming clinical study with uTRACE®. Likewise, we have finalised the contract with the CRO partner for our upcoming Phase 2 trial in prostate cancer with a 64Cu-labeled version of uTRACE®.

Outlook for Curasight

Curasight is expanding and accelerating its clinical therapeutic strategy with the addition of a new Phase I/IIa basket trial to include a total of five cancer indications in the same trial. The trial will investigate Curasight's theranostic approach by testing the diagnosis platform uTRACE® and treatment platform uTREAT® in:

- Brain cancer (Glioblastoma)
- Neuroendocrine tumors (NET)
- Head and Neck cancer
- Non-Small Cell Lung cancers (NSCLC), and
- Pancreatic cancer.

The new Phase I/IIa basket trial will apply Curasight's uPAR theranostic platform approach combining diagnosis (uTRACE®) and therapy (uTREAT®) and expect to initiate this trial in 2025.

Curasight is committed to accelerating the development of its uTREAT® therapeutic platform in order to develop both uTREAT® and its diagnosis platform uTRACE® in parallel, to deliver better options to patients with certain types of cancer.

Furthermore, Curasight is looking into how to unfold further our platform and how to broaden the mission to realize the vast potential of uTRACE® for diagnosing and uTREAT® for targeted radionuclide therapy in other cancer types where uPAR is also expressed.

About high grade glioma and glioblastoma

Treatment of glioblastoma presents a significant unmet medical need, necessitating innovative and effective treatments. Curasight's research and development efforts aim to address this challenge and improve the lives of patients facing aggressive brain cancer. Curasight's first goal is to advance its lead platforms uTREAT® (used for therapy) and uTRACE® (used for diagnosing) to improve outcomes for the approx. 65,000 patients in the US and EU diagnosed annually with brain tumours. Accordingly, approximately 30,000 patients are diagnosed each year with high-grade glioma where the prognosis is very poor. Glioblastoma is a rare disease in both markets, qualifying for Orphan Drug Designation; moreover, because of the high unmet need, platforms targeting it are more likely to qualify for e.g. Priority Review, Breakthrough Therapy Designation, or Accelerated Approval. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50 % of the patients die within 14 months and after five years from diagnosis only 5 % are still alive.

About neuroendocrine tumors

Each year approximately 35,000 new cases are diagnosed in the US and EU. Due to the long survival of these patients, more than 400,000 patients are living with the disease in the US and EU. Neuroendocrine tumors are a rare form of cancer that occurs in glandular cells most frequently in the lining of the gastrointestinal tract or in the lungs, but the disease can in principle occur in all organs of the body. The main findings from the phase II trial with uTRACE® were that uPAR-positive lesions were seen in most NET patients and that uPAR PET was prognostic, and that uPAR will be a promising target for therapy in NET patients.

About head and neck cancer

Head and neck squamous cell carcinoma is the 6th most common cancer worldwide with 890,000 new cases and 450,000 deaths in 2018. The incidence is anticipated to increase over the coming years. The main finding from the Phase II trial using uTRACE® was that patients with high uptake on uPAR-PET compared to those with a low uptake had an 8.5-fold poorer prognosis regarding relapse-free survival. The conclusion from the trial was that uPAR-PET could become valuable regarding planning of therapy and follow-up in head and neck cancer patients. In addition, the presence of uPAR in head and neck cancer patients and in particular, in those with the most aggressive disease, also formed the basis for pursuing uPAR-targeted radionuclide therapy (uTREAT®) in this cancer type.

About Non Small Cell Lung Cancer (NSCLC)

Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women. NSCLC is the most common type of lung cancer with approximately 700,000 patients being diagnosed each year in the US and EU alone. The 5-year survival rate in the US is around 28 %. Despite advances, there is a need for more effective therapies. Curasight's preclinical studies show uTREAT® effective in treating non-small cell lung cancer (NSCLC). Preliminary data from the investigator-initiated study presented at WMIC in Praque last year, demonstrates that almost all NSCLC tumors are uPAR positive and thus would be eligible for uTREAT®.

About Pancreatic Cancer

Pancreatic cancer is the 12th most common cancer worldwide. It is the 12th most common cancer in men and the 11th most common cancer in women. There were more than 495,000 new cases of pancreatic cancer in 2020. Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. The pancreas is a gland located deep in the abdomen, between the stomach and the spine. It makes enzymes that help digestion and hormones that control blood-sugar levels. More than 66,000 Americans are expected to be diagnosed with pancreatic cancer in 2024.

Strategic partnerships

Due to the very encouraging results from the finalised investigator-initiated clinical phase-II study in Prostate Cancer, Curasight has entered into a collaborative partnership with Curium to accelerate the product development of uTRACE® as a more flexible and non-invasive risk stratification tool compared to the present gold standard (biopsy), for prostate cancer patients entering or being followed in active surveillance programs. The first milestone payment Curium has been received by us.

To support and accelerate the strategic business development, discussions are currently ongoing with a number of major pharma companies with a view to uncover opportunities and interest in uTRACE® and uTREAT®.

Key clinical milestones 2024

(i)	**H1 2024:** Accelerated development of the therapeutic platform
(ii)	**H1 2024:** uTRACE® – First patient dosed – part I in uTRACE ph 2 trial (Curium partnership)
(iii)	**H1 2024:** uTRACE® Milestone payment for enrolment 1st patient in - part I in uTRACE ph 2 trial (Curium partnership)
(iv)	**H2 2024:** uTRACE® – preliminary efficacy data – part I in uTRACE ph 2 trail (Curium partnership)

Therapeutic Program

Pre-clinical | Phase I | Phase II | Phase III

Sponsor: Curasight
Diagnostic platform: uTRACE® and uTREAT®

GBM
Glioblastoma (Brain cancer)

NSCLC
Non-Small Cell Lung cancers

NEN
Neuroendocrine neoplasms

HNSCC
Head & Neck Cancer

PaC
Pancreatic cancer



*A basket trial is designed to simultaneously evaluate treatments for multiple tumors in a single clinical trial. Curasight will investigate cancer therapy with uTREAT® in selected cancer diseases known to express uPAR.

Partnered Project

Pre-clinical | Phase I | Phase II | Phase III

Sponsor: Curasight
Partner: Curium Inc.
Diagnostic platform: uTRACE®

Prostate Cancer*

*) Investigated for diagnostic performance for non-invasive classification of ISUP grades among patients with localised, untreated prostate cancer.
**) Investigator-initiated study

Investigator Initiated Trials

utrace DIAGNOSTIC SOLUTIONS

Pre-clinical → Phase I → Phase II → Phase III

Sponsor: National University Hospital of Denmark (Rigshospitalet)
Diagnostic platform: uTRACE®

GBM Glioblastoma (Brain cancer)	Completed
PCa Prostate cancer	Completed
NEN Neuroendocrine neoplasms	Completed
HNSCC Head & Neck Cancer	Completed
NSCLC Non-Small Cell Lung cancer	Ongoing
BC Breast cancer	Completed
UBC Urinary bladder cancer	Completed**

Results from uTRACE® IITs are used as supportive data in ongoing partner project with Curium as well as in potential future partnering projects and in the planning of our therapeutic program with a theranostic approach.

*) Investigator Initiated Trails = IITs, >400 patients have received utrace in these Investigator Initiated Trials

**) Completed with fewer patients than planned for technical reasons

Analyses

SEB initiated its commissioned research on June 18, 2021, and has since then continuously monitored and analyzed Curasight's operations, platforms, markets, and competitors.

SEB's corporate page on Curasight is available at the following link:
https://research.sebgroup.com/corporate/companies/2853/overview

Redeye initiated its commissioned research on October 25, 2023, and will continuously monitor and analyze Curasight's operations, platforms, markets, and competitors.

SEB's corporate page on Curasight is available at the following link:
https://www.redeye.se/company/curasight

KapitalPartner initiated its commissioned research on August 2021, and has since then continuously monitored and analyzed Curasight's operations, platforms, markets, and competitors.

KapitalPartner's corporate page on Curasight is available at the following link:
https://kapitalpartner.dk/curasight/

Corporate Information

Shareholders

The table below presents the management's shareholdings in Curasight.

Name	Votes & capital (%)
AK 2014 Holding ApS[1]	30,24
UK Curacap ApS[2]	20,01
CHN Holding ApS[3]	12,11
Madsen Holding 2013 ApS[4]	4,57
LT 2003 ApS[5]	2,95
Charlotte Vedel[6]	0,20
Hanne Damgaard Jensen[7]	0,20
Kirsten Drejer[8]	0,02

1. Owned by co-founder, CSO, and Board Member Andreas Kjaer
2. Owned by CEO and Board Member Ulrich Krasilnikoff
3. Owned by co-founder Carsten H Nielsen
4. Owned by Co-founder and Director CMC, Jacob Madsen
5. Owned by Deputy Chairman of the Board, Lars Trolle
6. Member of the Board of Directors
7. CDO & COO
8. Chair of the Board of Directors**

The share

The shares of Curasight A/S were listed on Spotlight Stock Market on October 8, 2020. The short name/ticker is CURAS, and the ISIN code is DK0061295797. As of March 31, 2024, the number of shares was 19,893,891 (19,893,891). All shares have equal rights to the Company's assets and results.

Long-term incentive program

Curasight has a long-term incentive program covering the financial years 2022-2025 with a total of 956,770 warrants covering the Company's Board of Directors, Executive Management and other key employees. For the Board of Directors, a total of 229,230 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 11,461.50 nominally worth of shares in the Company. The warrants are allocated between Lars Trolle (dept. chairman of the Board of Directors), Charlotte Vedel (member of the Board of Directors) and Kirsten Aarup Drejer (Chair of the Board of Directors**).

For the Executive Management and other key employees of the Company, a total of 727,540 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 36,377.00 nominally worth of shares in the Company. The warrants are allocated between Ulrich Krasilnikoff (CEO), Andreas Kjær (CSO), Hanne Damgaard Jensen (CDO), Nic Gillings (Head of Quality Assurance and Regulatory Affairs) and Jacob Madsen (Director CMC).

Risks

A number of risk factors can affect Curasight's operations. It is therefore of great importance to consider relevant risks in addition to the Company's growth opportunities. For a detailed description of the risks attributable to the Company and its shares, please refer to the prospectus published by the Company in 2020. The prospectus is available on Curasight's website: www.curasight.com/investor/ipo-2020/

Accounting policy

The interim report is presented in accordance with the provisions of the Danish Financial Statements Act (Årsregnskabsloven) for enterprises in reporting class B with application of provisions for a higher reporting class.

Auditor's review

The interim report has not been reviewed by the Company's auditor.

Financial calendar	
Interim report Q2 2024	August 22, 2024
Interim report Q3 2024	November 21, 2024

**) Elected Chair of the Board after the end of the period.

Financial statements

Income statement

Operating loss before tax for the first quarter of 2024 amounted to kDKK -9,367 (kDKK -6,184).

Loss before depreciation, amortisation and impairments for the first quarter amounted to kDKK -9,172 (kDKK -6,005) of which staff expenses was kDKK -1,787 (kDKK -1,349).

Loss before depreciation, amortisation and impairments comprise of revenue, clinical expenses, patent expenses, staff expenses and other business expenses.

Balance sheet

Per March 31, 2024, the Company's balance sheet amounted to kDKK 27,574 (54,745). The assets consisted primarily of acquired IP-rights totaling kDKK 7,438 related to the development of uTRACE® and uTREAT® and cash amounted to kDKK 11,877. The equity and liabilities consisted primarily of an equity totaling kDKK 23,391.

Cash flow

Curasight's cash flow from operating activities in Q1 2024 amounted to kDKK -8,203. This post was primarily affected by the Company's loss for the period of kDKK -7,992.

Cash as of March 31, 2024, was kDKK 11,877 (kDKK 43,975).



Income statement

(kDKK)	Q1 2024*	Q1 2023*	Q1-Q4 2023
Gross loss	**-7,385**	**-4,656**	**-25,729**
Staff expenses	-1,787	-1,349	-6,395
Loss before depreciation, amortisation, write-downs and impairment losses	**-9,172**	**-6,005**	**-32,124**
Depreciation, amortisation and impairment of intangible assets and property, plant and equipment	-204	-179	-1,090
Operating loss	**-9,376**	**-6,184**	**-33,214**
Net financial expenses	9	-2	-6
Loss before tax	**-9,367**	**-6,186**	**-33,220**
Tax on loss for the period	1,375	1,360	7,051
Loss for the period	**-7,992**	**-4,826**	**-26,169**

*) Unaudited figures

Balance sheet - Assets

(kDKK)	2024-03-31*	2023-03-31*	2023-12-31
Acquired patents	7,438	6,872	7,641
Intangible assets	**7,438**	**6,872**	**7,641**
Other fixtures and fittings, tools and equipment	0	129	0
Property, plant and equipment	**0**	**129**	**0**
Deposits	51	44	51
Total investments	**51**	**44**	**51**
Total non-current assets	**7,489**	**7,045**	**7,693**
Other receivables	1,333	2,563	5,469
Income tax receivables	6,875	1,162	5,500
Total receivables	**8,208**	**3,725**	**10,969**
Cash at bank and in hand	11,877	43,975	20,080
Total current assets	**20,085**	**47,700**	**31,049**
Assets	**27,574**	**54,745**	**38,742**

*) Unaudited figures

Balance sheet - Liabilities and equity

(kDKK)	2024-03-31*	2023-03-31*	2023-12-31
Share capital	995	995	995
Retained earnings	22,396	51,731	30,388
Equity	**23,391**	**52,726**	**31,383**
Trade payables	3,944	718	6,922
Deferred income	0	1,128	0
Other payables	239	173	437
Short term-debt	**4,183**	**2,019**	**7,359**
Debt	**4,183**	**2,019**	**7,359**
Liabilities and equity	**27,574**	**54,745**	**38,742**

*) Unaudited figures

Equity - Q1* 2024

(kDKK) Change in equity Q1 2024	Share capital	Share Premium Account	Retained earnings	Total
Equity at 1 January 2024	**995**	**0**	**30,388**	**31,383**
Net profit/loss for the period	0	0	-7,992	-7,992
Equity at 31 March 2024	**995**	**0**	**22,396**	**23,391**

Equity - Q1* 2023

(kDKK) Change in equity Q1 2023	Share capital	Share Premium Account	Retained earnings	Total
Equity at 1 January 2023	**995**	**0**	**56,557**	**57,552**
Net profit/loss for the period	0	0	-4,826	-4,826
Equity at 31 March 2023	**995**	**0**	**51,731**	**52,726**

Equity - FY 2023

(kDKK) Change in equity Q1-Q4 2023	Share capital	Share Premium Account	Retained earnings	Total
Equity at 1 January 2023	**995**	**0**	**56,557**	**57,552**
Net profit/loss for the period	0	0	-26,169	-26,169
Equity at 31 December 2023	**995**	**0**	**30,388**	**31,383**

*) Unaudited figures

Cash flow statement

(kDKK)	Q1 2024*	Q1 2023*	Q1-Q4 2023
Loss for the period	-7,992	-4,826	-26,169
Adjustments	-1,162	179	-5,894
Change in working capital	960	-2,681	1,073
Cash flow from operating activities before net financials	**-8,194**	**-7,328**	**-30,990**
Interest expenses and similar expenses paid	-9	-2	-6
Income tax received/paid	0	1,360	1,139
Cash flow from operating activities	**-8,203**	**-5,970**	**-29,857**
Change in deposits	0	0	-8
Purchase of intangible assets	0	0	0
Cash flows from investing activities	**0**	**0**	**-8**
Total cash flows for the period	**-8,203**	**-5,970**	**-29,865**
Cash, beginning of the period	20,080	49,945	49,945
Cash, end of the period	**11,877**	**43,975**	**20,080**
Cash, end of the period	11,877	43,975	20,080
Total	**11,877**	**43,975**	**20,080**

*) Unaudited figures

Statement by the Board of Directors

The Board of Directors provide their assurance that the interim report provides a fair and true overview of the Company's operations, financial position, and results.

København N, May 23, 2024
Curasight A/S

Board of Directors

Kirsten Drejer
Chair of the Board

Lars Trolle
Dept. chair of the Board

Charlotte Vedel
Board member

Andreas Kjær
Board member

Ulrich Krasilnikoff
Board member and CEO

Contact information
Curasight A/S
Ole Maaløes Vej 3
2200 Copenhagen, Denmark
Email: info@curasight.com
Phone: +4522830160

curasight

Curasight's team are pioneers behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy, with the precise uTRACE® diagnostics.